Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · July 19, 2022

Cardiopulmonary Exercise Testing Demonstrates the Impact of Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy

Circulation: Heart Failure


Additional Info

Circulation: Heart Failure
Impact of Tafamidis and Optimal Background Treatment on Physical Performance in Patients With Transthyretin Amyloid Cardiomyopathy
Circ Heart Fail 2022 Jun 29;[EPub Ahead of Print], R Badr Eslam, B Öztürk, R Rettl, CDJ Capelle, H Qin, C Binder, TM Dachs, L Camuz Ligios, F Duca, D Dalos, L Schrutka, F Alasti, J Kastner, G Vila, D Bonderman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading